We clearly demonstrate that the mutation status of β-catenin determines ABCB1 expression in a defined cell line model and in colon cancer specimens; however, no correlation of this finding with chemosensitivity towards 24 MDR-related and non-related antitumour compounds was detected. Here, ABCB1 is linked to colonic neoplasm.